All news

News

Lilly’s oral GLP-1 resolves sleep apnea in Phase 3 — changing telehealth logistics

Eli Lilly’s daily pill orforglipron (Foundayo) successfully treats sleep apnea in Phase 3 trials. Learn what this oral GLP-1 means for online buyers.

By CompareRx Editorial Team · Medically reviewed by CompareRx Medical Review Desk
Published
A close-up of a daily prescription pill representing oral GLP-1 sleep apnea treatment options.

Key takeaways

  • Eli Lilly's daily oral GLP-1 orforglipron significantly reduced sleep apnea severity in two Phase III trials.
  • For patients using PAP therapy: Those on orforglipron experienced an AHI reduction of 17.3 events per hour, compared to 5.3 events per hour in the placebo cohort.
  • Side effects: Like injectable GLP-1s, gastrointestinal issues were common. Side effects occurred in roughly 68% to 71% of patients taking orforglipron, compared to about 37% of those taking a placebo.

Compare providers side by side or read the full GLP-1 guides.

Key takeaways

  • Eli Lilly's daily oral GLP-1 orforglipron significantly reduced sleep apnea severity in two Phase III trials.

What happened

At the American Heart Association (AHA) annual meeting in Chicago, researchers presented landmark data from the ATTAIN-OSA Phase III clinical trials demonstrating that Eli Lilly’s once-daily oral GLP-1 drug, orforglipron (marketed as Foundayo), significantly improves moderate-to-severe obstructive sleep apnea (OSA). Published simultaneously in JAMA, the results show that the daily weight-loss pill drastically reduces nighttime breathing interruptions and lowers key cardiovascular risk factors. If finalized, these findings position orforglipron to potentially become the first-ever oral, needle-free medication approved to treat obstructive sleep apnea.

Why it matters

This development is a massive shift for US consumers who buy weight-loss medications online. Currently, patients looking to treat both obesity and sleep apnea must rely on injectable medications like Zepbound (tirzepatide), which require strict cold-chain shipping to prevent the proteins from degrading.

As a non-peptide, small-molecule drug, orforglipron is chemically stable at room temperature. An oral tablet eliminates the need for refrigerated transport, specialized packaging, and needles. For telehealth buyers, this could drastically lower shipping overhead, eliminate the anxiety of self-injection, and open up more affordable, direct-to-consumer prescription models that fit easily into a daily routine.

What the data says

The ATTAIN-OSA program consisted of two 52-week, double-blind trials evaluating 712 adults across 66 international sites, all of whom had moderate-to-severe sleep apnea and a body mass index (BMI) of 27 or higher. Participants were randomized to receive either a placebo or a once-daily orforglipron tablet escalated to their maximum tolerated dose (9 mg, 14.5 mg, or 17.2 mg).

According to the data reported by Dr. Vaishnavi Kundel of the Icahn School of Medicine at Mount Sinai, the results were highly significant:

  • For patients not using continuous positive airway pressure (PAP) machines: Those taking orforglipron saw their apnea-hypopnea index (AHI) drop by an average of 17.8 events per hour, compared to a reduction of just 4.5 events per hour for the placebo group.
  • For patients using PAP therapy: Those on orforglipron experienced an AHI reduction of 17.3 events per hour, compared to 5.3 events per hour in the placebo cohort.
  • Secondary benefits: Orforglipron led to major improvements in sleep apnea-specific hypoxic burden (oxygen deprivation), overall body weight, systolic blood pressure, and high-sensitivity C-reactive protein (an inflammatory marker).
  • [Side effects](/glp-1-side-effects): Like injectable GLP-1s, gastrointestinal issues were common. Side effects occurred in roughly 68% to 71% of patients taking orforglipron, compared to about 37% of those taking a placebo.

How it compares

While a daily pill represents a giant leap forward in convenience, clinical trial commentators noted that injectable alternatives still hold a efficacy edge. Dr. Ildiko Lingvay of the University of Texas Southwestern Medical Center compared the ATTAIN-OSA data to existing data for tirzepatide (Zepbound), which is already FDA-approved for obstructive sleep apnea.

Injectable tirzepatide yields greater absolute reductions in AHI, a more pronounced reduction in hypoxic burden, and a more established safety record. Furthermore, tirzepatide is already FDA-approved to reduce cardiovascular risks in patients with type 2 diabetes, whereas orforglipron’s long-term cardiovascular risk reduction has not yet been formally established.

However, compared to PAP therapy—which Dr. Michael Grandner of the University of Arizona noted has notoriously low long-term patient compliance due to the bulky, uncomfortable equipment—a daily pill offers an incredibly accessible alternative or companion therapy.

How this fits the bigger picture

The rise of oral GLP-1 alternatives is poised to disrupt the telehealth marketplace, where cash-paying consumers frequently compare convenience and cost. As discussed in our detailed guide on /lilly-foundayo-pill-sleep-apnea-telehealth-math, having a needle-free option changes the financial math for patients who do not want to manage cold-chain logistics.

Historically, weight-loss drugs have faced steep barriers to access. As highlighted in our analysis of how /glp1-weight-loss-use-overtakes-diabetes-telehealth-buyers, the primary driver of the GLP-1 market has shifted overwhelmingly toward weight management and its associated comorbidities. Obesity-related sleep apnea is one of the most common comorbidities that can help patients qualify for treatment. By securing clinical trial data for both weight loss and OSA, Eli Lilly is building a dual-indication profile for orforglipron that mirrors Zepbound, but in an easier-to-distribute oral form.

This oral option could eventually compete with compounded formulations. Many patients currently turn to telehealth providers listed on our /providers directory to access more affordable options, but a mass-produced, room-temperature-stable tablet could eventually lower the retail price floor for brand-name therapy.

What happens next

Now that the Phase III ATTAIN-OSA data has been published and presented, Eli Lilly will likely leverage these results to seek an expanded FDA indication for orforglipron to treat obstructive sleep apnea, building on its existing regulatory pathway.

In the meantime, medical experts suggest that pragmatic clinical trials will be needed to study how orforglipron performs when combined directly with physical therapies like PAP machines or oral appliances. Patients shopping for weight-loss solutions can continue to monitor regulatory approvals and explore current options using the CompareRx /compare tool.

Disclaimer: CompareRx is an independent consumer information portal and does not provide medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider before starting or changing any medication regimen.

Find the provider that fits your budget

Compare 100+ online GLP-1 providers on true monthly cost, or get your top 3 matches in 90 seconds.

More from the newsroom

Popular comparisons

Sources

Community

What do you make of this?

Add your take, ask a question, or tell us what you're seeing with your own provider — our editors read every thread.

Medical disclaimer: CompareRx.org is an independent comparison site and publisher. This article is informational only, is not medical advice, and is not a substitute for care from a licensed clinician. Read our medical disclaimer, editorial policy and affiliate disclosure.